Income StatementBalance SheetCash FlowSegments
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals Cash Flow Statement

Operating, investing, and financing cash movements

Regeneron Pharmaceuticals generated $5.0B in operating cash flow over the trailing twelve months. After $899.7M in capital expenditures, free cash flow was $4.1B. Free cash flow increased 0.3% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$5.0BNet Cash From Investing (TTM)-$2.9BNet Cash From Financing (TTM)-$3.4BCapital Expenditures (TTM)$899.7MDepreciation And Amortization Cf (TTM)$540.0MNet Change In Cash (TTM)-$122.4M
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$67.0B
P/E Ratio15.14
ROE14.55%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other non-cash income (expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Change in accounts payable$225.6M-$214.1M$216.4M$759.2M$0.0$107.7M
Change in accounts receivable$117.8M-$657.8M———-$1.2M
Change in deferred revenue$0.0$17.7M-$142.9M—-$3.1M$99.6M
Change in inventories$117.7M$152.3M$42.5M$82.6M$0.0-$26.6M
Depreciation and amortization$126.4M$126.9M$135.1M$136.7M$145.0M$123.2M
Other operating reconciliation adjustments$345.1M$236.4M-$247.2M$158.7M$326.1M$351.7M
Other Non-Cash Income (Expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other Non-cash Income (Expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other Non-cash Income (Expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Net cash from operating activities$1.3B$1.0B$1.1B$1.6B$1.2B$1.1B
Net income$917.7M$808.7M$1.4B$1.5B$844.6M$727.2M
Other non-cash income (expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Increase (Decrease) in Deferred Income Taxes$280.2M$139.1M$135.2M$278.6M$232.5M$96.0M
Increase (Decrease) in Prepaid Expense and Other Assets$55.3M$179.5M$230.7M$47.9M—$198.6M
Other Noncash Income (Expense)-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other Non-cash Income and Expense-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other Non-Cash Adjustments-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Other Non-Cash Income and Expense-$68.0M-$3.2M$20.9M-$16.3M-$136.9M-$55.6M
Stock-based compensation$304.4M$255.7M$251.7M$237.0M$249.3M$257.4M
Adjustments to Reconcile Net Income to Operating Cash Flow$345.1M$236.4M-$247.2M$158.7M$326.1M$351.7M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$199.6M$229.3M$219.0M$201.4M$248.7M$230.6M
Payments To Acquire Intangible Assets1$67.4M$42.2M$187.8M$43.3M$42.0M$48.9M
Net cash from investing activities—$647.5M-$1.1B-$402.9M—-$428.9M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Dividends paid$0.0$93.8M$92.6M$91.2M$92.7M$97.8M
Other, net$0.0-$10.3M———$0.0
Payment of Deferred Purchase Consideration$0.0-$10.3M———$0.0
Noncontrolling interest transactions and other$0.0-$10.3M———$0.0
Net cash from financing activities-$1.1B-$1.1B-$1.1B-$717.9M-$780.1M-$802.2M
Noncontrolling Interests Activity and Other$0.0-$10.3M———$0.0
Proceeds from issuance of common stock$90.9M$60.6M$31.5M$40.3M$503.5M$163.1M
Repurchases of common stock$973.0M$1.0B$1.1B$664.0M$671.7M$794.3M
Taxes paid for net share settlement$253.4M$4.3M$5.6M$3.0M$519.2M$73.2M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.1B$815.8M$925.4M$1.4B$922.0M$848.3M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$700.0K$600.0K$400.0K——-$900.0K
Net increase (decrease) in cash—$604.0M-$1.1B$497.5M$610.6M-$153.1M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$13.2M$10.4M$10.4M$10.4M$10.4M—